Clinical trial
A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
NCT01483963 is registered in ClinicalTrials.gov with Endo USA Inc., a Keenova Therapeutics Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2a, Open-label, Dose-ranging Study of the Safety and Effectiveness of AA4500 for the Treatment of Adhesive Capsulitis of the Shoulder
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics Company
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2011
- Completion date
- February 28, 2013
- Enrollment
- 50 (actual)
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.
adhesive capsulitis, frozen shoulder